Education

• BS, Zoology; BA, Molecular Biology, University of Texas at Austin, 1998
• MD, The University of Texas at Houston Medical School, 2003
• Residency, University of Utah Division of Urology, Salt Lake City, UT, 2008
• Fellowship, Urologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2010

Dr. Abel specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.

Clinical Specialties

Dr. Abel is certified by the American Board of Urology. He performs open and laparoscopic surgery including surgery using the daVinci robot. Dr Abel’s philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.

Research Interests

Dr. Abel conducts clinical, translational, and basic research in urologic oncology. He currently is involved in several projects focusing on the development and metastasis of kidney cancer.

Recent Publications

• Abel EJ, Wood CG, Eickstaedt N, Fang JE, Kenney P, Bagrodia A, Youssef RF, Sagalowsky AI, Margulis V. Preoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus. J. Urol. 2013 Feb 19.
  [PubMed ID: 23434945]
  More Information
• Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur. Urol. 2013 May; 63(5):947-52.
  [PubMed ID: 23273681]
  More Information
• Patel SR, Abel EJ, Hedican SP, Nakada SY. Ablation of small renal masses: practice patterns at academic institutions in the United States. J. Endourol. 2013 Feb; 27(2):158-61.
  [PubMed ID: 22974005]
  More Information
• Abel EJ, Carrasco A, Culp SH, Matin SF, Tamboli P, Tannir NM, Wood CG. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int. 2012 Dec; 110(11):1742-6.
  [PubMed ID: 22503066]
  More Information
• Masterson TA, Carver BS, Abel EJ, Pettus JA, Bosl GJ, Sheinfeld J. Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. BJU Int. 2012 Oct; 110(7):950-5.
  [PubMed ID: 22394608]
  More Information
• Abel EJ, Karam JA, Carrasco A, Matin SF. Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma. J. Endourol. 2011 Aug; 25(8):1323-7.
  [PubMed ID: 21774667, PMCID: 3148128]
  More Information
• Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur. Urol. 2011 Dec; 60(6):1273-9.
  [PubMed ID: 21784574]
  More Information
• Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur. Urol. 2011 Jun; 59(6):912-8.
  [PubMed ID: 21367518]
  More Information
• Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur. Urol. 2011 Apr; 59(4):619-28.
  [PubMed ID: 21167632]
  More Information
• Abel EJ, Culp SH, Meissner M, Matin SF, Tamboli P, Wood CG. Identifying the risk of disease progression after surgery for localized renal cell carcinoma. BJU Int. 2010 Nov; 106(9):1277-83.
  [PubMed ID: 20394619]
  More Information